BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61. [PMID: 21862407 DOI: 10.1016/S1470-2045(11)70214-5] [Cited by in Crossref: 771] [Cited by in F6Publishing: 399] [Article Influence: 77.1] [Reference Citation Analysis]
Number Citing Articles
1 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget 2017;8:60750-63. [PMID: 28977823 DOI: 10.18632/oncotarget.18490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7:308-322. [PMID: 23148997 DOI: 10.1016/j.molonc.2012.10.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
3 Kieffer Y, Bonneau C, Popova T, Rouzier R, Stern MH, Mechta-Grigoriou F. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Front Genet 2020;11:219. [PMID: 32256521 DOI: 10.3389/fgene.2020.00219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Reinbolt RE, Hays JL. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol 2013;3:237. [PMID: 24098868 DOI: 10.3389/fonc.2013.00237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
5 Min A, Lee KH, Im SA. DNA Damage Repair Inhibitor for Breast Cancer Treatment. Adv Exp Med Biol 2021;1187:159-79. [PMID: 33983578 DOI: 10.1007/978-981-32-9620-6_8] [Reference Citation Analysis]
6 Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov 2018;8:1404-21. [PMID: 30213835 DOI: 10.1158/2159-8290.CD-18-0474] [Cited by in Crossref: 124] [Cited by in F6Publishing: 67] [Article Influence: 41.3] [Reference Citation Analysis]
7 Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs R D. 2020;20:55-73. [PMID: 32215876 DOI: 10.1007/s40268-020-00301-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
8 Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018;24:701-16. [PMID: 28913723 DOI: 10.1007/s12253-017-0307-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 2014;5:3361. [PMID: 24553445 DOI: 10.1038/ncomms4361] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 19.3] [Reference Citation Analysis]
10 Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet 2015;6:96. [PMID: 25852742 DOI: 10.3389/fgene.2015.00096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
11 Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer. Sci Rep 2017;7:7505. [PMID: 28790402 DOI: 10.1038/s41598-017-07617-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
12 Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;12:3013-9. [PMID: 30271116 DOI: 10.2147/DDDT.S164553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
13 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 11.2] [Reference Citation Analysis]
14 Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, Gautam S, Begum R. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 2016;49:421-437. [PMID: 27329285 DOI: 10.1111/cpr.12268] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
15 Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res 2014;6:77-92. [PMID: 24600246 DOI: 10.2147/CMAR.S50497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
16 Song L, McNeil EM, Ritchie AM, Astell KR, Gourley C, Melton DW. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ. BMC Cancer 2017;17:864. [PMID: 29254481 DOI: 10.1186/s12885-017-3864-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019;201:94-102. [PMID: 31128155 DOI: 10.1016/j.pharmthera.2019.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 25.0] [Reference Citation Analysis]
18 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 14.2] [Reference Citation Analysis]
19 Zhang J, Dai Q, Park D, Deng X. Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) 2016;7:E51. [PMID: 27548226 DOI: 10.3390/genes7080051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 9.4] [Reference Citation Analysis]
20 Nakagawa Y, Sedukhina AS, Okamoto N, Nagasawa S, Suzuki N, Ohta T, Hattori H, Roche-Molina M, Narváez AJ, Jeyasekharan AD, Bernal JA, Sato K. NF-κB signaling mediates acquired resistance after PARP inhibition. Oncotarget 2015;6:3825-39. [PMID: 25686825 DOI: 10.18632/oncotarget.2868] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
21 Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther 2019;20:1035-45. [PMID: 30929564 DOI: 10.1080/15384047.2019.1595279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 2017;22:655-66. [PMID: 28469042 DOI: 10.1634/theoncologist.2016-0430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 2014;6:229-39. [PMID: 25342990 DOI: 10.1177/1758834014544121] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 17.1] [Reference Citation Analysis]
24 Moore KN, Monk BJ. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016;21:954-63. [PMID: 27256873 DOI: 10.1634/theoncologist.2015-0268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
25 Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012;13:1523-35. [PMID: 23057551 DOI: 10.2217/pgs.12.137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
26 Ghosal G, Chen J. DNA damage tolerance: a double-edged sword guarding the genome. Transl Cancer Res 2013;2:107-29. [PMID: 24058901 DOI: 10.3978/j.issn.2218-676X.2013.04.01] [Cited by in F6Publishing: 78] [Reference Citation Analysis]
27 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
28 Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Med 2018;7:1285-96. [PMID: 29479816 DOI: 10.1002/cam4.1318] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
29 Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 2015;113 Suppl 1:S3-9. [PMID: 26669452 DOI: 10.1038/bjc.2015.394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
30 Bradbury A, O'Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers (Basel) 2020;12:E1939. [PMID: 32709004 DOI: 10.3390/cancers12071939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. Oncol Lett 2020;20:90. [PMID: 32831909 DOI: 10.3892/ol.2020.11951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res 2014;16:R25. [PMID: 24625110 DOI: 10.1186/bcr3625] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
33 Wagner LM. Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 2015;8:1931-9. [PMID: 26251615 DOI: 10.2147/OTT.S69935] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
34 Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol 2017;28:e39. [PMID: 28541631 DOI: 10.3802/jgo.2017.28.e39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
35 Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 2019;20:570-80. [PMID: 30880072 DOI: 10.1016/S1470-2045(18)30905-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 30] [Article Influence: 36.5] [Reference Citation Analysis]
36 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
37 Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol 2018;23:45-51. [PMID: 29185095 DOI: 10.1007/s10147-017-1208-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
38 Dong Q, Du Y, Li H, Liu C, Wei Y, Chen MK, Zhao X, Chu YY, Qiu Y, Qin L, Yamaguchi H, Hung MC. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res 2019;79:819-29. [PMID: 30573522 DOI: 10.1158/0008-5472.CAN-18-1273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
39 Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018;119:1401-1409. [PMID: 30353044 DOI: 10.1038/s41416-018-0274-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 22.3] [Reference Citation Analysis]
40 Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71. [PMID: 22759740 DOI: 10.1097/CCO.0b013e3283564230] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
41 Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49:2972-2978. [PMID: 23810467 DOI: 10.1016/j.ejca.2013.05.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 14.5] [Reference Citation Analysis]
42 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
43 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106:dju089. [PMID: 24842883 DOI: 10.1093/jnci/dju089] [Cited by in Crossref: 96] [Cited by in F6Publishing: 110] [Article Influence: 13.7] [Reference Citation Analysis]
44 Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 2012;135:505-17. [PMID: 22875744 DOI: 10.1007/s10549-012-2188-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
45 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
46 Sun C, Cao W, Qiu C, Li C, Dongol S, Zhang Z, Dong R, Song K, Yang X, Zhang Q, Kong B. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. J Hematol Oncol 2020;13:9. [PMID: 32005272 DOI: 10.1186/s13045-020-0844-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
47 Hedström E, Pederiva C, Farnebo J, Nodin B, Jirström K, Brennan DJ, Farnebo M. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis 2015;6:e1892. [PMID: 26426684 DOI: 10.1038/cddis.2015.250] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
48 Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011;10:4074-82. [PMID: 22101337 DOI: 10.4161/cc.10.23.18170] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
49 Li D, Hu C, Yang J, Liao Y, Chen Y, Fu SZ, Wu JB. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma. Int J Nanomedicine 2020;15:10045-58. [PMID: 33328733 DOI: 10.2147/IJN.S272730] [Reference Citation Analysis]
50 Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013;10:688-96. [PMID: 24129347 DOI: 10.1038/nrclinonc.2013.177] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
51 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
52 Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107-18. [PMID: 23459506 DOI: 10.2147/OTT.S30238] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
53 Zhou Z, Patel M, Ng N, Hsieh MH, Orth AP, Walker JR, Batalov S, Harris JL, Liu J. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer 2014;14:944. [PMID: 25495526 DOI: 10.1186/1471-2407-14-944] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
54 Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". Diagnostics (Basel) 2019;9:E55. [PMID: 31109041 DOI: 10.3390/diagnostics9020055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
55 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 32.4] [Reference Citation Analysis]
56 Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014;133:599-606. [PMID: 24631446 DOI: 10.1016/j.ygyno.2014.03.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 9.6] [Reference Citation Analysis]
57 Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K. Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. J Ovarian Res 2013;6:35. [PMID: 23663277 DOI: 10.1186/1757-2215-6-35] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
58 Ocana A, Pandiella A. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget 2017;8:22218-34. [PMID: 28108739 DOI: 10.18632/oncotarget.14731] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
59 Yang KS, Kohler RH, Landon M, Giedt R, Weissleder R. Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci Rep 2015;5:10129. [PMID: 25984718 DOI: 10.1038/srep10129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
60 Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M, Scambia G, Sette C. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. J Exp Clin Cancer Res 2021;40:116. [PMID: 33789687 DOI: 10.1186/s13046-021-01917-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30:903-15. [PMID: 32276934 DOI: 10.1136/ijgc-2020-001288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
62 Park SH, Chung YM, Ma J, Yang Q, Berek JS, Hu MC. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. Oncotarget 2016;7:42110-25. [PMID: 27283899 DOI: 10.18632/oncotarget.9881] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
63 Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411-424. [PMID: 22713970 DOI: 10.1038/nrm3376] [Cited by in Crossref: 712] [Cited by in F6Publishing: 650] [Article Influence: 79.1] [Reference Citation Analysis]
64 Abramson VG, Mayer IA. Molecular Heterogeneity of Triple Negative Breast Cancer. Curr Breast Cancer Rep 2014;6:154-8. [PMID: 25419441 DOI: 10.1007/s12609-014-0152-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
65 Giedt RJ, Koch PD, Weissleder R. Single cell analysis of drug distribution by intravital imaging. PLoS One 2013;8:e60988. [PMID: 23593370 DOI: 10.1371/journal.pone.0060988] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
66 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer 2017;3:31. [PMID: 28948212 DOI: 10.1038/s41523-017-0025-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
67 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
68 Sama AR, Schilder RJ. Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management. Int J Womens Health 2014;6:149-57. [PMID: 24511245 DOI: 10.2147/IJWH.S40889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM. FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. J Genet Couns 2018;27:131-9. [PMID: 28780754 DOI: 10.1007/s10897-017-0130-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
70 Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg 2020;9:1149-63. [PMID: 32953630 DOI: 10.21037/gs-20-413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Sci Rep 2017;7:42319. [PMID: 28176879 DOI: 10.1038/srep42319] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
72 Patel L, Parker B, Yang D, Zhang W. Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biol Med 2013;10:214-20. [PMID: 24349831 DOI: 10.7497/j.issn.2095-3941.2013.04.005] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
73 Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, Masson JY. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules 2015;5:3204-59. [PMID: 26610585 DOI: 10.3390/biom5043204] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
74 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49. [PMID: 29238749 DOI: 10.1038/s41523-017-0052-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
75 Zhou P, Wang J, Mishail D, Wang CY. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med. 2020;3:187-201. [PMID: 32983586 DOI: 10.1093/pcmedi/pbaa030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
76 Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013;169:1745-65. [PMID: 23682925 DOI: 10.1111/bph.12244] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
77 Terret C, Russo C. Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. Drugs Aging 2018;35:93-115. [PMID: 29388072 DOI: 10.1007/s40266-018-0519-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 2017;16:1279-89. [PMID: 28500233 DOI: 10.1158/1535-7163.MCT-16-0740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
79 Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M, Olsen E, Thomas DG, Zhang A, Hirsh N, Ritter CL, Liu M, Nyati S, Pierce LJ, Jagsi R, Speers C. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Mol Cancer Ther 2019;18:2063-73. [PMID: 31413177 DOI: 10.1158/1535-7163.MCT-19-0520] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
80 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
81 Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. [PMID: 27558151 DOI: 10.1038/nrdp.2016.61] [Cited by in Crossref: 300] [Cited by in F6Publishing: 248] [Article Influence: 60.0] [Reference Citation Analysis]
82 Iijima M, Banno K, Okawa R, Yanokura M, Iida M, Takeda T, Kunitomi-Irie H, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Tominaga E, Aoki D. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. Oncol Lett 2017;13:1063-70. [PMID: 28454214 DOI: 10.3892/ol.2017.5582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
83 Joy AA, Ghosh M, Fernandes R, Clemons MJ. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol 2015;22:S29-42. [PMID: 25848337 DOI: 10.3747/co.22.2360] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
84 Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol 2015;5:123. [PMID: 26082895 DOI: 10.3389/fonc.2015.00123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
85 Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology 2017;282:453-63. [PMID: 27841728 DOI: 10.1148/radiol.2016161929] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
86 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 135.0] [Reference Citation Analysis]
87 De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol 2013;3:228. [PMID: 24062981 DOI: 10.3389/fonc.2013.00228] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
88 Ghonim MA, Pyakurel K, Ibba SV, Al-Khami AA, Wang J, Rodriguez P, Rady HF, El-Bahrawy AH, Lammi MR, Mansy MS, Al-Ghareeb K, Ramsay A, Ochoa A, Naura AS, Boulares AH. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med 2015;13:225. [PMID: 26169874 DOI: 10.1186/s12967-015-0583-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
89 Sui H, Shi C, Yan Z, Li H. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Drug Des Devel Ther 2015;9:3183-90. [PMID: 26124641 DOI: 10.2147/DDDT.S82035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
90 Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev 2013;22:1677-86. [PMID: 23880734 DOI: 10.1158/1055-9965.EPI-13-0391] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
91 Herzog TJ, Monk BJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecol Oncol Res Pract 2017;4:13. [PMID: 28904804 DOI: 10.1186/s40661-017-0050-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
92 Muñoz-Galván S, Carnero A. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells 2020;9:E1402. [PMID: 32512891 DOI: 10.3390/cells9061402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
93 Weaver AN, Yang ES. Beyond DNA Repair: Additional Functions of PARP-1 in Cancer. Front Oncol. 2013;3:290. [PMID: 24350055 DOI: 10.3389/fonc.2013.00290] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 14.3] [Reference Citation Analysis]
94 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 486] [Article Influence: 115.2] [Reference Citation Analysis]
95 Turk AA, Wisinski KB. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 2018;124:2498-506. [PMID: 29660759 DOI: 10.1002/cncr.31307] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
96 Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Int J Biol Sci 2019;15:962-72. [PMID: 31182917 DOI: 10.7150/ijbs.30721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
97 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
98 Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764-75. [PMID: 24240112 DOI: 10.1158/1078-0432.CCR-13-2287] [Cited by in Crossref: 499] [Cited by in F6Publishing: 252] [Article Influence: 62.4] [Reference Citation Analysis]
99 Adams DJ. The Valley of Death in anticancer drug development: a reassessment. Trends Pharmacol Sci 2012;33:173-80. [PMID: 22410081 DOI: 10.1016/j.tips.2012.02.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
100 Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol 2016;27 Suppl 1:i1-3. [PMID: 27141062 DOI: 10.1093/annonc/mdw082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
101 Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE. PARP-1 regulates DNA repair factor availability. EMBO Mol Med 2018;10:e8816. [PMID: 30467127 DOI: 10.15252/emmm.201708816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
102 Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol 2018;23:36-44. [PMID: 28884397 DOI: 10.1007/s10147-017-1182-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
103 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 37] [Cited by in F6Publishing: 91] [Article Influence: 7.4] [Reference Citation Analysis]
104 Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V. The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer. J Clin Med 2020;9:E2239. [PMID: 32679669 DOI: 10.3390/jcm9072239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
105 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
106 Kim KM, Moon YJ, Park SH, Park HJ, Wang SI, Park HS, Lee H, Kwon KS, Moon WS, Lee DG, Kim JR, Jang KY. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. PLoS One 2016;11:e0163193. [PMID: 27643881 DOI: 10.1371/journal.pone.0163193] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
107 Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 2017;8:97657-70. [PMID: 29228641 DOI: 10.18632/oncotarget.18280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
108 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br J Cancer 2015;113:396-402. [PMID: 26180927 DOI: 10.1038/bjc.2015.256] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
109 Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med 2016;109:98-105. [PMID: 26933155 DOI: 10.1177/0141076816631154] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
110 Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, Navarro JM, Perez RB, Masson JY, Bachvarov D. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. J Transl Med 2020;18:439. [PMID: 33213473 DOI: 10.1186/s12967-020-02613-4] [Reference Citation Analysis]
111 Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget 2019;10:2855-68. [PMID: 31080557 DOI: 10.18632/oncotarget.26869] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
112 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
113 Armstrong SR, Narendrula R, Guo B, Parissenti AM, McCallum KL, Cull S, Lannér C. Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res 2012;5:40. [PMID: 23194409 DOI: 10.1186/1757-2215-5-40] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
114 Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74:287-97. [PMID: 24240700 DOI: 10.1158/0008-5472.CAN-13-2541] [Cited by in Crossref: 188] [Cited by in F6Publishing: 114] [Article Influence: 23.5] [Reference Citation Analysis]
115 Biau J, Chautard E, Verrelle P, Dutreix M. Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. Front Oncol 2019;9:1009. [PMID: 31649878 DOI: 10.3389/fonc.2019.01009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
116 Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P. Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors. Front Oncol 2020;10:1415. [PMID: 32903519 DOI: 10.3389/fonc.2020.01415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
117 McQuade RM, Stojanovska V, Stavely R, Timpani C, Petersen AC, Abalo R, Bornstein JC, Rybalka E, Nurgali K. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol 2018;175:656-77. [PMID: 29194564 DOI: 10.1111/bph.14114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
118 Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014;3:1579-94. [PMID: 25124282 DOI: 10.1002/cam4.317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
119 Zhou D, Chu W, Xu J, Jones LA, Peng X, Li S, Chen DL, Mach RH. Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem 2014;22:1700-7. [PMID: 24503274 DOI: 10.1016/j.bmc.2014.01.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
120 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
121 Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Int J Gynecol Cancer 2016;26:255-60. [PMID: 26745694 DOI: 10.1097/IGC.0000000000000591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
122 Park SH, Noh SJ, Kim KM, Bae JS, Kwon KS, Jung SH, Kim JR, Lee H, Chung MJ, Moon WS, Kang MJ, Jang KY. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients. Transl Oncol 2015;8:239-49. [PMID: 26310369 DOI: 10.1016/j.tranon.2015.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
123 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
124 Gao A, Guo M. Epigenetic based synthetic lethal strategies in human cancers. Biomark Res 2020;8:44. [PMID: 32974031 DOI: 10.1186/s40364-020-00224-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
125 González-Martín A, Sánchez-Lorenzo L, Bratos R, Márquez R, Chiva L. First-line and maintenance therapy for ovarian cancer: current status and future directions. Drugs 2014;74:879-89. [PMID: 24848752 DOI: 10.1007/s40265-014-0221-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
126 Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013;14:537-45. [PMID: 23760496 DOI: 10.4161/cbt.24349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
127 Wang Z, Gao J, Zhou J, Liu H, Xu C. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer. J Gynecol Oncol 2019;30:e26. [PMID: 30740957 DOI: 10.3802/jgo.2019.30.e26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
128 Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 2018;102:233-48. [PMID: 29394989 DOI: 10.1016/j.ajhg.2017.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
129 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
130 Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8. [PMID: 24202391 DOI: 10.1038/nm.3369] [Cited by in Crossref: 269] [Cited by in F6Publishing: 228] [Article Influence: 33.6] [Reference Citation Analysis]
131 Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X, Liu K. The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res 2013;6:74. [PMID: 24165045 DOI: 10.1186/1757-2215-6-74] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
132 Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92. [PMID: 24286369 DOI: 10.1186/bcr3493] [Cited by in Crossref: 231] [Cited by in F6Publishing: 189] [Article Influence: 28.9] [Reference Citation Analysis]
133 Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer 2016;16:725. [PMID: 27613518 DOI: 10.1186/s12885-016-2754-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
134 Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E828. [PMID: 32235500 DOI: 10.3390/cancers12040828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
135 Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer. Int J Biol Sci 2016;12:1500-10. [PMID: 27994514 DOI: 10.7150/ijbs.16176] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
136 Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014;111:651-9. [PMID: 25025963 DOI: 10.1038/bjc.2014.345] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
137 Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, Sobol H, Birnbaum D, Borg JP, Charafe-Jauffret E, Gonçalves A. Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. PLoS One 2014;9:e104302. [PMID: 25144364 DOI: 10.1371/journal.pone.0104302] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
138 Mouchiroud L, Houtkooper RH, Auwerx J. NAD⁺ metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013;48:397-408. [PMID: 23742622 DOI: 10.3109/10409238.2013.789479] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 15.6] [Reference Citation Analysis]
139 Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 2012;118:5283-92. [PMID: 22517119 DOI: 10.1002/cncr.27568] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
140 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 808] [Article Influence: 180.6] [Reference Citation Analysis]
141 Delgado-Balderas JR, Garza-Rodriguez ML, Gomez-Macias GS, Barboza-Quintana A, Barboza-Quintana O, Cerda-Flores RM, Miranda-Maldonado I, Vazquez-Garcia HM, Valdez-Chapa LD, Antonio-Macedo M, Dean M, Barrera-Saldaña HA. Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine. Genes (Basel) 2018;9:E349. [PMID: 29997359 DOI: 10.3390/genes9070349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
142 McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018;7:212540. [PMID: 30116283 DOI: 10.7573/dic.212540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
143 Wang W, Duan B, Zeng L. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts]. Zhongguo Fei Ai Za Zhi 2016;19:16-23. [PMID: 26805733 DOI: 10.3779/j.issn.1009-3419.2016.01.02] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
144 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials 2016;17:293. [PMID: 27323902 DOI: 10.1186/s13063-016-1423-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
145 Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 2016;7:76534-50. [PMID: 27708213 DOI: 10.18632/oncotarget.12266] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 40.7] [Reference Citation Analysis]
146 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
147 Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther 2015;14:920-30. [PMID: 25824335 DOI: 10.1158/1535-7163.MCT-14-0474] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
148 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
149 Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, Bebb DG. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014;13:2129-2137. [PMID: 24841718 DOI: 10.4161/cc.29212] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 12.4] [Reference Citation Analysis]
150 Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88. [PMID: 24063698 DOI: 10.1186/bcr3484] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 17.6] [Reference Citation Analysis]
151 Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2015;:CD007929. [PMID: 25991068 DOI: 10.1002/14651858.CD007929.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
152 Solimando DA Jr, Waddell JA. Nivolumab and Olaparib. Hosp Pharm 2015;50:356-66. [PMID: 26405320 DOI: 10.1310/hpj5005-356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
153 Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLoS Med 2016;13:e1002193. [PMID: 27959926 DOI: 10.1371/journal.pmed.1002193] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
154 Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. J Immunother Cancer. 2019;7:197. [PMID: 31345267 DOI: 10.1186/s40425-019-0680-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 19.5] [Reference Citation Analysis]
155 Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012;11:479-97. [PMID: 22653217 DOI: 10.1038/nrd2372] [Cited by in Crossref: 218] [Cited by in F6Publishing: 204] [Article Influence: 24.2] [Reference Citation Analysis]
156 Ruiz PD, Hamilton GA, Park JW, Gamble MJ. MacroH2A1 Regulation of Poly(ADP-Ribose) Synthesis and Stability Prevents Necrosis and Promotes DNA Repair. Mol Cell Biol 2019;40:e00230-19. [PMID: 31636161 DOI: 10.1128/MCB.00230-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
157 Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 2015;235:25-36. [PMID: 25230372 DOI: 10.1002/path.4443] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 9.6] [Reference Citation Analysis]
158 Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, Jungbluth AA, Frosina D, Slotkin E, Shukla N, Meyers P, Healey JH, Hameed M, Ladanyi M. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clin Cancer Res 2019;25:6346-56. [PMID: 31175097 DOI: 10.1158/1078-0432.CCR-18-4032] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
159 Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer 2016;8:15-25. [PMID: 26997874 DOI: 10.4137/BIC.S36679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
160 Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 2016;7:27208-19. [PMID: 27028851 DOI: 10.18632/oncotarget.8349] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
161 Lopez J, Banerjee S, Kaye SB. New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol 2013;24 Suppl 10:x69-76. [PMID: 24265409 DOI: 10.1093/annonc/mdt475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
162 Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep 2016;18:29. [PMID: 26984416 DOI: 10.1007/s11912-016-0515-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
163 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel). 2019;11. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
164 Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer 2019:ijgc-2019-000499. [PMID: 31118216 DOI: 10.1136/ijgc-2019-000499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
165 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
166 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
167 Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012;17:956-62. [PMID: 22673632 DOI: 10.1634/theoncologist.2012-0028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
168 Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol 2020;38:1164-74. [PMID: 32073956 DOI: 10.1200/JCO.19.02745] [Cited by in Crossref: 51] [Cited by in F6Publishing: 13] [Article Influence: 51.0] [Reference Citation Analysis]
169 Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clin Cancer Res 2020;26:4268-79. [PMID: 32398324 DOI: 10.1158/1078-0432.CCR-20-0056] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 33.0] [Reference Citation Analysis]
170 Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine 2019;40:375-81. [PMID: 30635165 DOI: 10.1016/j.ebiom.2018.12.060] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 19.0] [Reference Citation Analysis]
171 Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. Int J Mol Sci 2021;22:7884. [PMID: 34360649 DOI: 10.3390/ijms22157884] [Reference Citation Analysis]
172 Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget 2017;8:47154-60. [PMID: 28454085 DOI: 10.18632/oncotarget.17005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
173 Sohrabji F, Park MJ, Mahnke AH. Sex differences in stroke therapies. J Neurosci Res 2017;95:681-91. [PMID: 27870437 DOI: 10.1002/jnr.23855] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
174 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
175 Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14. [PMID: 25218906 DOI: 10.1016/S1470-2045(14)70391-2] [Cited by in Crossref: 362] [Cited by in F6Publishing: 168] [Article Influence: 51.7] [Reference Citation Analysis]
176 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 141] [Article Influence: 25.8] [Reference Citation Analysis]
177 Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018;10:e9172. [PMID: 30377213 DOI: 10.15252/emmm.201809172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 32.0] [Reference Citation Analysis]
178 Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 2019;79:311-9. [PMID: 30482774 DOI: 10.1158/0008-5472.CAN-18-1003] [Cited by in Crossref: 162] [Cited by in F6Publishing: 91] [Article Influence: 54.0] [Reference Citation Analysis]
179 Chang S, Sharan SK. BRCA1 and microRNAs: emerging networks and potential therapeutic targets. Mol Cells 2012;34:425-32. [PMID: 22936386 DOI: 10.1007/s10059-012-0118-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
180 Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2016;78:525-31. [PMID: 27422301 DOI: 10.1007/s00280-016-3106-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
181 Smolle E, Taucher V, Pichler M, Petru E, Lax S, Haybaeck J. Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci 2013;14:9536-55. [PMID: 23644885 DOI: 10.3390/ijms14059536] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
182 Huang TT, Lampert EJ, Coots C, Lee JM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev 2020;86:102021. [PMID: 32311593 DOI: 10.1016/j.ctrv.2020.102021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
183 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
184 Zhang Z, Lian X, Xie W, Quan J, Liao M, Wu Y, Yang ZZ, Wang G. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Sci Rep 2020;10:20924. [PMID: 33262410 DOI: 10.1038/s41598-020-77908-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Fields EC, McGuire WP, Lin L, Temkin SM. Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Front Oncol 2017;7:177. [PMID: 28871275 DOI: 10.3389/fonc.2017.00177] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
186 Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776-82. [PMID: 23047548 DOI: 10.1038/bjc.2012.451] [Cited by in Crossref: 332] [Cited by in F6Publishing: 271] [Article Influence: 36.9] [Reference Citation Analysis]
187 Kohn EC, Romano S, Lee JM. Clinical implications of using molecular diagnostics for ovarian cancers. Ann Oncol 2013;24 Suppl 10:x22-26. [PMID: 24265398 DOI: 10.1093/annonc/mdt464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
188 Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211. [PMID: 23621985 DOI: 10.1186/1471-2407-13-211] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
189 Sehouli J, Braicu EI, Chekerov R. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives. Geburtshilfe Frauenheilkd 2016;76:164-9. [PMID: 26941449 DOI: 10.1055/s-0035-1558185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
190 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 83.0] [Reference Citation Analysis]
191 Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Med 2015;13:217. [PMID: 26354718 DOI: 10.1186/s12916-015-0454-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
192 Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014;34:3828-42. [PMID: 25092866 DOI: 10.1128/MCB.01646-13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
193 Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma. Cancer Res Treat 2020;52:634-44. [PMID: 32019284 DOI: 10.4143/crt.2019.207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
194 Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. PLoS One 2014;9:e95649. [PMID: 24748377 DOI: 10.1371/journal.pone.0095649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
195 Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Chen S, Huang Z, Zheng X, Huang D, Hu Y. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clin Med Insights Oncol 2021;15:1179554921996288. [PMID: 33737855 DOI: 10.1177/1179554921996288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
196 Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. PLoS One 2015;10:e0128066. [PMID: 26043110 DOI: 10.1371/journal.pone.0128066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
197 Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One 2015;10:e0126867. [PMID: 25962155 DOI: 10.1371/journal.pone.0126867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
198 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017;9:519-31. [PMID: 28794804 DOI: 10.1177/1758834017714993] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
199 Davis SL, Eckhardt SG, Tentler JJ, Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 2014;6:88-100. [PMID: 24790649 DOI: 10.1177/1758834013519843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
200 Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K. An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome. South Asian J Cancer 2020;9:6. [PMID: 31956609 DOI: 10.4103/sajc.sajc_157_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
201 Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949-58. [PMID: 23315029 DOI: 10.1007/s10637-012-9922-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
202 Mieulet V, Garnier C, Kieffer Y, Guilbert T, Nemati F, Marangoni E, Renault G, Chamming's F, Vincent-Salomon A, Mechta-Grigoriou F. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Sci Rep 2021;11:4219. [PMID: 33603134 DOI: 10.1038/s41598-021-83685-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
203 Lightfoot M, Montemorano L, Bixel K. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development? Curr Oncol Rep 2020;22:29. [PMID: 32067102 DOI: 10.1007/s11912-020-0873-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
204 Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119:1075-85. [PMID: 30353045 DOI: 10.1038/s41416-018-0271-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
205 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
206 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
207 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012;29:807-19. [PMID: 22692561 DOI: 10.1007/s10585-012-9496-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
208 Jiang Q, Greenberg RA. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 2015;290:17724-32. [PMID: 26048987 DOI: 10.1074/jbc.R115.667931] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
209 O'Neil NJ, Bailey ML, Hieter P. Synthetic lethality and cancer. Nat Rev Genet 2017;18:613-23. [PMID: 28649135 DOI: 10.1038/nrg.2017.47] [Cited by in Crossref: 236] [Cited by in F6Publishing: 171] [Article Influence: 59.0] [Reference Citation Analysis]
210 Brown JM, Wasson MD, Marcato P. The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs. Cells 2020;9:E763. [PMID: 32244924 DOI: 10.3390/cells9030763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
211 Schiewer MJ, Knudsen KE. DNA Damage Response in Prostate Cancer. Cold Spring Harb Perspect Med 2019;9:a030486. [PMID: 29530944 DOI: 10.1101/cshperspect.a030486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
212 Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012;26:649-70, ix. [PMID: 22520984 DOI: 10.1016/j.hoc.2012.02.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
213 Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018;19:E3249. [PMID: 30347758 DOI: 10.3390/ijms19103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 22.6] [Reference Citation Analysis]
215 Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs. 2016;34:450-457. [PMID: 27075016 DOI: 10.1007/s10637-016-0351-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
216 Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 2012;17:430-40. [PMID: 22926640 DOI: 10.1007/s10147-012-0459-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
217 Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 2014;5:2678-87. [PMID: 24798692 DOI: 10.18632/oncotarget.1929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
218 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
219 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. Front Oncol 2021;11:686776. [PMID: 34262869 DOI: 10.3389/fonc.2021.686776] [Reference Citation Analysis]
221 Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42. [PMID: 28008141 DOI: 10.18632/oncotarget.14021] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 26.0] [Reference Citation Analysis]
222 Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol 2018;36:46-60. [PMID: 29319699 DOI: 10.1038/nbt.4017] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 20.7] [Reference Citation Analysis]
223 Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. J Ovarian Res 2015;8:1. [PMID: 25884701 DOI: 10.1186/s13048-015-0124-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
224 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 116] [Article Influence: 26.6] [Reference Citation Analysis]
225 To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014;7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.CAPR-14-0047] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 6.6] [Reference Citation Analysis]
226 Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F. Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition. Cancer Res 2012;72:5547-55. [PMID: 22962264 DOI: 10.1158/0008-5472.CAN-12-0934] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
227 Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL. Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers (Basel) 2019;11:E354. [PMID: 30871186 DOI: 10.3390/cancers11030354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
228 Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Ann Oncol 2014;25:2372-8. [PMID: 25281711 DOI: 10.1093/annonc/mdu461] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
229 Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 2017;8:87044-53. [PMID: 29152062 DOI: 10.18632/oncotarget.19667] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
230 Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, Wang F, Zhu Y, Zhao Y, Wu Y, Qin Z, Sun X, Ren B, Jiang B, Jin W, Shen Z, Tang Z, Song X, Wang L, Liu X, Zhou C, Jiang B. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 2020;22:431-40. [PMID: 32652442 DOI: 10.1016/j.neo.2020.06.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
231 Mensah LB, Morton SW, Li J, Xiao H, Quadir MA, Elias KM, Penn E, Richson AK, Ghoroghchian PP, Liu J, Hammond PT. Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. Bioeng Transl Med 2019;4:e10131. [PMID: 31249881 DOI: 10.1002/btm2.10131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
232 Dal Molin GZ, Omatsu K, Sood AK, Coleman RL. Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Ther Adv Med Oncol 2018;10:1758835918778483. [PMID: 29977351 DOI: 10.1177/1758835918778483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
233 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
234 Zhang JX, Li DQ, He AR, Motwani M, Vasiliou V, Eswaran J, Mishra L, Kumar R. Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology 2012;55:1840-51. [PMID: 22223166 DOI: 10.1002/hep.25566] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
235 Makvandi M, Xu K, Lieberman BP, Anderson RC, Effron SS, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH. A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Res 2016;76:4516-24. [PMID: 27261505 DOI: 10.1158/0008-5472.CAN-16-0416] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
236 Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014;106:dju029. [PMID: 24627272 DOI: 10.1093/jnci/dju029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
237 Yamamoto KN, Hirota K, Takeda S, Haeno H. Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One 2014;9:e105724. [PMID: 25158060 DOI: 10.1371/journal.pone.0105724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
238 Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clin Cancer Res 2018;24:3163-75. [PMID: 29615458 DOI: 10.1158/1078-0432.CCR-18-0204] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 16.3] [Reference Citation Analysis]
239 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
240 Kwon M, Jang H, Kim EH, Roh JL. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Cell Cycle 2016;15:3105-14. [PMID: 27686740 DOI: 10.1080/15384101.2016.1235104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
241 Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer 2020;20:204. [PMID: 32164585 DOI: 10.1186/s12885-020-6693-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
242 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
243 Makhale A, Nanayakkara D, Raninga P, Khanna KK, Kalimutho M. CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer. Int J Mol Sci 2021;22:5782. [PMID: 34071360 DOI: 10.3390/ijms22115782] [Reference Citation Analysis]
244 Petersen AH, Aagaard MM, Nielsen HR, Steffensen KD, Waldstrøm M, Bojesen A. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. Eur J Hum Genet 2016;24:1104-11. [PMID: 26733283 DOI: 10.1038/ejhg.2015.268] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
245 Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol 2012;23:53-64. [PMID: 22355468 DOI: 10.3802/jgo.2012.23.1.53] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
246 Zhang F, Ren C, Zhao H, Yang L, Su F, Zhou MM, Han J, Sobie EA, Walsh MJ. Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. Oncotarget 2016;7:71620-34. [PMID: 27690302 DOI: 10.18632/oncotarget.12287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
247 Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 2013;24:83-91. [PMID: 23346317 DOI: 10.3802/jgo.2013.24.1.83] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
248 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137-1154. [PMID: 26463832 DOI: 10.1158/2159-8290.cd-15-0714] [Cited by in Crossref: 347] [Cited by in F6Publishing: 190] [Article Influence: 57.8] [Reference Citation Analysis]
249 Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP; ENIGMA consortium. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat 2014;35:151-64. [PMID: 24323938 DOI: 10.1002/humu.22478] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
250 Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017;2:e000208. [PMID: 29018573 DOI: 10.1136/esmoopen-2017-000208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
251 Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget 2017;8:6057-66. [PMID: 28002809 DOI: 10.18632/oncotarget.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
252 Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016;14:267. [PMID: 27634150 DOI: 10.1186/s12967-016-1027-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
253 Seligson ND, Kautto EA, Passen EN, Stets C, Toland AE, Millis SZ, Meyer CF, Hays JL, Chen JL. BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma. Oncologist 2019;24:973-9. [PMID: 30541756 DOI: 10.1634/theoncologist.2018-0448] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
254 OʼSullivan Coyne G, Chen A, Kummar S. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 2015;27:475-81. [PMID: 26447876 DOI: 10.1097/CCO.0000000000000238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
255 Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012;9:359-66. [PMID: 22473105 DOI: 10.1038/nrclinonc.2012.48] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
256 Curtin NJ. The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers (Basel) 2020;12:E564. [PMID: 32121331 DOI: 10.3390/cancers12030564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
257 Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 2018;23:123-33. [PMID: 29595348 DOI: 10.1080/14728214.2018.1459563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
258 Thurber GM, Yang KS, Reiner T, Kohler RH, Sorger P, Mitchison T, Weissleder R. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 2013;4:1504. [PMID: 23422672 DOI: 10.1038/ncomms2506] [Cited by in Crossref: 136] [Cited by in F6Publishing: 118] [Article Influence: 17.0] [Reference Citation Analysis]
259 Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M, Hulbert-Williams NJ; GTEOC Study Group. Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access. J Genet Couns 2017;26:1280-91. [PMID: 28540621 DOI: 10.1007/s10897-017-0108-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
260 Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet 2018;50:1262-70. [PMID: 30104763 DOI: 10.1038/s41588-018-0179-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 96] [Article Influence: 46.3] [Reference Citation Analysis]
261 Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD. Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells. Biotechnol Bioeng 2017;114:2085-95. [PMID: 28322442 DOI: 10.1002/bit.26293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
262 Ledermann JA, El-Khouly F. PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. Br J Cancer 2015;113 Suppl 1:S10-6. [PMID: 26669450 DOI: 10.1038/bjc.2015.395] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
263 Hu X, Huang W, Fan M. Emerging therapies for breast cancer. J Hematol Oncol 2017;10:98. [PMID: 28454587 DOI: 10.1186/s13045-017-0466-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
264 AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol 2016;143:379-88. [PMID: 27614696 DOI: 10.1016/j.ygyno.2016.08.328] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
265 Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am 2013;27:737-49, viii. [PMID: 23915742 DOI: 10.1016/j.hoc.2013.05.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
266 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
267 Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget 2017;8:40152-68. [PMID: 27374179 DOI: 10.18632/oncotarget.10308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
268 Yang H, Jaeger M, Walker A, Wei D, Leiker K, Weitao T. Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing. J Cancer 2018;9:219-31. [PMID: 29344267 DOI: 10.7150/jca.22554] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
269 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 130] [Article Influence: 37.2] [Reference Citation Analysis]
270 Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104. [PMID: 30356138 DOI: 10.1038/s41571-018-0114-z] [Cited by in Crossref: 285] [Cited by in F6Publishing: 230] [Article Influence: 142.5] [Reference Citation Analysis]
271 Yamashita H, Nakayama K, Ishikawa M, Ishibashi T, Nakamura K, Sawada K, Yoshimura Y, Tatsumi N, Kurose S, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. Int J Mol Sci 2019;20:E5129. [PMID: 31623180 DOI: 10.3390/ijms20205129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
272 Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020;22:61. [PMID: 32517735 DOI: 10.1186/s13058-020-01296-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 77.0] [Reference Citation Analysis]
273 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
274 Liu GY, Zhang W. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? Chin J Cancer 2012;31:1-4. [PMID: 22176776 DOI: 10.5732/cjc.011.10432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
275 Dobbelstein M, Sørensen CS. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov 2015;14:405-23. [PMID: 25953507 DOI: 10.1038/nrd4553] [Cited by in Crossref: 177] [Cited by in F6Publishing: 143] [Article Influence: 29.5] [Reference Citation Analysis]
276 Zhao J, Li Y, Gao J, De Y. Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways. Oncol Lett 2017;14:5569-74. [PMID: 29142606 DOI: 10.3892/ol.2017.6873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
277 Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801-17. [PMID: 23175119 DOI: 10.1038/nrc3399] [Cited by in Crossref: 593] [Cited by in F6Publishing: 519] [Article Influence: 74.1] [Reference Citation Analysis]
278 Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121:8-16. [PMID: 25043972 DOI: 10.1002/cncr.28914] [Cited by in Crossref: 169] [Cited by in F6Publishing: 167] [Article Influence: 24.1] [Reference Citation Analysis]
279 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
280 Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2019;120:279-85. [PMID: 30655615 DOI: 10.1038/s41416-018-0349-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
281 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 723] [Article Influence: 220.5] [Reference Citation Analysis]
282 Han Y, Yu X, Li S, Tian Y, Liu C. New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Front Oncol 2020;10:578095. [PMID: 33324554 DOI: 10.3389/fonc.2020.578095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
283 Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 2017;4:4. [PMID: 28250960 DOI: 10.1186/s40661-017-0039-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
284 Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 2018;10:E487. [PMID: 30518089 DOI: 10.3390/cancers10120487] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 26.3] [Reference Citation Analysis]
285 Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, Tweardy DJ, Lin SH, Chen J. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep 2016;15:843-56. [PMID: 27149849 DOI: 10.1016/j.celrep.2016.03.070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
286 Cheng H, Yang J, Liu H, Xiang Y. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2021;304:285-96. [PMID: 34021367 DOI: 10.1007/s00404-021-06070-2] [Reference Citation Analysis]
287 Zonneville J, Wang M, Alruwaili MM, Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Commun Biol 2021;4:862. [PMID: 34253820 DOI: 10.1038/s42003-021-02370-0] [Reference Citation Analysis]
288 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
289 Li CJ, Tzeng YT, Chiu YH, Lin HY, Hou MF, Chu PY. Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:2978. [PMID: 34198652 DOI: 10.3390/cancers13122978] [Reference Citation Analysis]
290 Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med 2018;8:a030635. [PMID: 29101113 DOI: 10.1101/cshperspect.a030635] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
291 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 137] [Article Influence: 26.7] [Reference Citation Analysis]
292 Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016;161:79-96. [PMID: 27000769 DOI: 10.1016/j.pharmthera.2016.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
293 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 37.0] [Reference Citation Analysis]
294 Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Res Treat 2020;182:491-502. [PMID: 32488393 DOI: 10.1007/s10549-020-05716-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health 2016;8:59-75. [PMID: 27051317 DOI: 10.2147/IJWH.S78101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
296 Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet 2020;97:54-63. [PMID: 31099061 DOI: 10.1111/cge.13566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
297 Chase DM, Patel S, Shields K. Profile of olaparib in the treatment of advanced ovarian cancer. Int J Womens Health 2016;8:125-9. [PMID: 27186080 DOI: 10.2147/IJWH.S55906] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
298 Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116:1021-6. [PMID: 28291774 DOI: 10.1038/bjc.2017.40] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
299 Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res 2018;37:30. [PMID: 29448954 DOI: 10.1186/s13046-018-0705-7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 29.7] [Reference Citation Analysis]
300 Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019;381:2403-15. [PMID: 31562800 DOI: 10.1056/NEJMoa1909707] [Cited by in Crossref: 234] [Cited by in F6Publishing: 98] [Article Influence: 117.0] [Reference Citation Analysis]
301 Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 2020;19:711-36. [PMID: 32884152 DOI: 10.1038/s41573-020-0076-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 37.0] [Reference Citation Analysis]
302 Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 2015;107:djv108. [PMID: 25995442 DOI: 10.1093/jnci/djv108] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
303 Sharma Saha S, Gentles L, Bradbury A, Brecht D, Robinson R, O'Donnell R, Curtin NJ, Drew Y. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers (Basel) 2021;13:1420. [PMID: 33804647 DOI: 10.3390/cancers13061420] [Reference Citation Analysis]
304 Zhang ZZ, Liu YJ, Yin XL, Zhan P, Gu Y, Ni XZ. Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. World J Gastroenterol. 2013;19:1968-1974. [PMID: 23569343 DOI: 10.3748/wjg.v19.i12.1968] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
305 Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J, Wu Q, Park DM, Yang C. Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl) 2019;97:1183-93. [PMID: 31201471 DOI: 10.1007/s00109-019-01802-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
306 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
307 Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 2016;22:194-201. [PMID: 26779812 DOI: 10.1038/nm.4032] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 21.2] [Reference Citation Analysis]
308 Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu LL, Azad NS. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res 2015;21:68-76. [PMID: 25355929 DOI: 10.1158/1078-0432.CCR-14-1552] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
309 Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 2018;6:163. [PMID: 29911111 DOI: 10.21037/atm.2018.04.35] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
310 Zhao EY, Jones M, Jones SJM. Whole-Genome Sequencing in Cancer. Cold Spring Harb Perspect Med 2019;9:a034579. [PMID: 29844223 DOI: 10.1101/cshperspect.a034579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
311 Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, Vinegoni C, Weissleder R. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 2012;14:169-77. [PMID: 22496617 DOI: 10.1593/neo.12414] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 8.2] [Reference Citation Analysis]
312 Sabatier R, Gonçalves A, Bertucci F, Capiello MA, Rousseau F, Lambaudie E, Chabannon C, Viens P, Extra JM. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res 2012;31:87. [PMID: 23072336 DOI: 10.1186/1756-9966-31-87] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
313 Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014;16:211. [PMID: 25093514 DOI: 10.1186/bcr3670] [Cited by in Crossref: 151] [Cited by in F6Publishing: 121] [Article Influence: 21.6] [Reference Citation Analysis]
314 Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK. Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int 2016;2016:2346585. [PMID: 27642590 DOI: 10.1155/2016/2346585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
315 Arranz EE, Vara JÁ, Gámez-Pozo A, Zamora P. Gene signatures in breast cancer: current and future uses. Transl Oncol 2012;5:398-403. [PMID: 23323153 DOI: 10.1593/tlo.12244] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
316 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20:e15-28. [PMID: 30614472 DOI: 10.1016/S1470-2045(18)30786-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 38] [Article Influence: 87.0] [Reference Citation Analysis]
317 Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N; kConFab Investigators. The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 2016;76:2778-90. [PMID: 27197267 DOI: 10.1158/0008-5472.CAN-16-0186] [Cited by in Crossref: 108] [Cited by in F6Publishing: 62] [Article Influence: 27.0] [Reference Citation Analysis]
318 Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer 2019;19:44. [PMID: 30630446 DOI: 10.1186/s12885-018-5250-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
319 Hu K, Wu W, Li Y, Lin L, Chen D, Yan H, Xiao X, Chen H, Chen Z, Zhang Y, Xu S, Guo Y, Koeffler HP, Song E, Yin D. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. EMBO Rep 2019;20:e46166. [PMID: 30940648 DOI: 10.15252/embr.201846166] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
320 Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, Lin J, Sheng Y, Yu Y. Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. Oncol Lett 2018;15:3068-74. [PMID: 29435039 DOI: 10.3892/ol.2017.7717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
321 Wang C, Fang H, Zhang J, Gu Y. Targeting "undruggable" c-Myc protein by synthetic lethality. Front Med 2021;15:541-50. [PMID: 33660217 DOI: 10.1007/s11684-020-0780-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
322 Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013;19:977-84. [PMID: 23269547 DOI: 10.1158/1078-0432.CCR-12-0163] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
323 George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 2017;14:284-96. [PMID: 27958297 DOI: 10.1038/nrclinonc.2016.191] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 18.0] [Reference Citation Analysis]
324 Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 2015;8:127-35. [PMID: 26309417 DOI: 10.2147/PGPM.S62809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
325 Huang TT, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, Thomas CJ, Lee JM. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. Cancer Res 2020;80:5380-92. [PMID: 32998994 DOI: 10.1158/0008-5472.CAN-20-1439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
326 Beggs AD, Dilworth MP. Surgery in the era of the 'omics revolution. Br J Surg 2015;102:e29-40. [PMID: 25627134 DOI: 10.1002/bjs.9722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
327 Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. BMC Med 2012;10:25. [PMID: 22401667 DOI: 10.1186/1741-7015-10-25] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 10.6] [Reference Citation Analysis]
328 Christodoulou EG, Yang H, Lademann F, Pilarsky C, Beyer A, Schroeder M. Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. Oncotarget 2017;8:34283-97. [PMID: 28415695 DOI: 10.18632/oncotarget.16079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
329 Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. Med Oncol 2017;34:33. [PMID: 28138868 DOI: 10.1007/s12032-017-0889-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
330 Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol 2015;9:1528-38. [PMID: 26004083 DOI: 10.1016/j.molonc.2015.04.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
331 Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015;75:628-34. [PMID: 25634215 DOI: 10.1158/0008-5472.CAN-14-2593] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
332 Iorio GC, Martini S, Arcadipane F, Ricardi U, Franco P. The role of radiotherapy in epithelial ovarian cancer: a literature overview. Med Oncol 2019;36:64. [PMID: 31165334 DOI: 10.1007/s12032-019-1287-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
333 Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget 2017;8:23891-904. [PMID: 28055979 DOI: 10.18632/oncotarget.14409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
334 Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol 2017;144:486-90. [PMID: 28109627 DOI: 10.1016/j.ygyno.2017.01.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
335 Dent P. PARP inhibitors are not all equal. Cancer Biol Ther 2013;14:873-4. [PMID: 24025256 DOI: 10.4161/cbt.26160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017;17:638. [PMID: 28886696 DOI: 10.1186/s12885-017-3639-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
337 Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117-132. [PMID: 23386910 DOI: 10.7150/jca.4925] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
338 Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 2014;134:331-7. [PMID: 24844596 DOI: 10.1016/j.ygyno.2014.05.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
339 Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 2013;32:95. [PMID: 24252502 DOI: 10.1186/1756-9966-32-95] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
340 Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013;6:1197-206. [PMID: 24043945 DOI: 10.2147/OTT.S30748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
341 Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647-58. [PMID: 29464354 DOI: 10.1007/s00280-018-3532-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
342 Teo MCC, Chia CS, Lim C, Tan GHC, Chia WK, Soo KC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients. Pleura Peritoneum 2017;2:171-9. [PMID: 30911648 DOI: 10.1515/pp-2017-0021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
343 O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 2015;3:257-75. [PMID: 26676166 DOI: 10.1016/j.bbacli.2015.03.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 30.7] [Reference Citation Analysis]
344 Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemother Pharmacol 2017;80:165-75. [PMID: 28577239 DOI: 10.1007/s00280-017-3346-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
345 Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer 2013;13:523. [PMID: 24191908 DOI: 10.1186/1471-2407-13-523] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
346 Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017;8:79175-87. [PMID: 29108297 DOI: 10.18632/oncotarget.16577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
347 Cseh AM, Fábián Z, Sümegi B, Scorrano L. Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. Oncotarget 2017;8:50221-39. [PMID: 28430591 DOI: 10.18632/oncotarget.16859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
348 Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res 2017;23:3097-108. [PMID: 27993965 DOI: 10.1158/1078-0432.CCR-16-2273] [Cited by in Crossref: 118] [Cited by in F6Publishing: 72] [Article Influence: 23.6] [Reference Citation Analysis]
349 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
350 Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013;11:2. [PMID: 23548133 DOI: 10.1186/1897-4287-11-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
351 Rosen EM. BRCA1 in the DNA damage response and at telomeres. Front Genet 2013;4:85. [PMID: 23802008 DOI: 10.3389/fgene.2013.00085] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
352 Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 2017;28:512-8. [PMID: 27993796 DOI: 10.1093/annonc/mdw672] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 25.8] [Reference Citation Analysis]
353 Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer 2015;6:378-98. [PMID: 26622941 DOI: 10.18632/genesandcancer.76] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
354 Jiang Y, Martin J, Alkadhimi M, Shigemori K, Kinchesh P, Gilchrist S, Kersemans V, Smart S, Thompson JM, Hill MA, O'Connor MJ, Davies BR, Ryan AJ. Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model. Br J Cancer 2021;124:1809-19. [PMID: 33742147 DOI: 10.1038/s41416-021-01296-y] [Reference Citation Analysis]
355 Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5:137. [PMID: 32728057 DOI: 10.1038/s41392-020-0199-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
356 Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013;109:1072-8. [PMID: 23867999 DOI: 10.1038/bjc.2013.389] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
357 Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016;160:65-83. [PMID: 26896565 DOI: 10.1016/j.pharmthera.2016.02.003] [Cited by in Crossref: 195] [Cited by in F6Publishing: 154] [Article Influence: 39.0] [Reference Citation Analysis]
358 Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun 2020;11:2662. [PMID: 32471999 DOI: 10.1038/s41467-020-16142-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 32.0] [Reference Citation Analysis]
359 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50. [PMID: 25366685 DOI: 10.1200/JCO.2014.56.2728] [Cited by in Crossref: 1000] [Cited by in F6Publishing: 500] [Article Influence: 142.9] [Reference Citation Analysis]
360 Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016;114:723-30. [PMID: 27002934 DOI: 10.1038/bjc.2016.41] [Cited by in Crossref: 91] [Cited by in F6Publishing: 66] [Article Influence: 18.2] [Reference Citation Analysis]
361 Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016;115:1313-20. [PMID: 27824811 DOI: 10.1038/bjc.2016.348] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
362 Keung MYT, Wu Y, Vadgama JV. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. J Clin Med 2019;8:E435. [PMID: 30934991 DOI: 10.3390/jcm8040435] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
363 Beniey M, Haque T, Hassan S. Translating the role of PARP inhibitors in triple-negative breast cancer. Oncoscience 2019;6:287-8. [PMID: 30800714 DOI: 10.18632/oncoscience.474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
364 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 13.8] [Reference Citation Analysis]
365 Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Clin Cancer Res 2020;26:5557-66. [PMID: 32576627 DOI: 10.1158/1078-0432.CCR-19-2300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
366 Nunes T, Hamdan D, Leboeuf C, El Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. Targeting Cancer Stem Cells to Overcome Chemoresistance. Int J Mol Sci 2018;19:E4036. [PMID: 30551640 DOI: 10.3390/ijms19124036] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 17.7] [Reference Citation Analysis]
367 Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 2017;28:727-32. [PMID: 27993805 DOI: 10.1093/annonc/mdw663] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 26.3] [Reference Citation Analysis]
368 Li H, Liu L, Chang H, Zou Z, Xing D. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer. Cell Death Dis 2018;9:137. [PMID: 29374168 DOI: 10.1038/s41419-017-0169-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
369 Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer 2016;114:713-5. [PMID: 27022824 DOI: 10.1038/bjc.2016.67] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 18.6] [Reference Citation Analysis]
370 Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 173] [Article Influence: 25.8] [Reference Citation Analysis]
371 Pavanello M, Chan IH, Ariff A, Pharoah PD, Gayther SA, Ramus SJ. Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E3046. [PMID: 33086730 DOI: 10.3390/cancers12103046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
372 Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs 2020;80:131-46. [PMID: 31823331 DOI: 10.1007/s40265-019-01235-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
373 Garber K. PARP inhibitors bounce back. Nat Rev Drug Discov. 2013;12:725-727. [PMID: 24080684 DOI: 10.1038/nrd4147] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
374 Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Front Oncol 2020;10:958. [PMID: 32612955 DOI: 10.3389/fonc.2020.00958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
375 Shen JP, Ideker T. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. J Mol Biol 2018;430:2900-12. [PMID: 29932943 DOI: 10.1016/j.jmb.2018.06.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
376 McGee J, Panabaker K, Leonard S, Ainsworth P, Elit L, Shariff SZ. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. Int J Gynecol Cancer 2017;27:437-43. [PMID: 28072594 DOI: 10.1097/IGC.0000000000000907] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
377 Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol 2016;142:548-56. [PMID: 27426307 DOI: 10.1016/j.ygyno.2016.07.092] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
378 Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells 2020;9:E719. [PMID: 32183385 DOI: 10.3390/cells9030719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
379 Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Womens Health (Lond) 2018;14:1745505717750694. [PMID: 29313444 DOI: 10.1177/1745505717750694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
380 Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012;19:3907-21. [PMID: 22788767 DOI: 10.2174/092986712802002464] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 8.7] [Reference Citation Analysis]
381 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 193] [Article Influence: 33.4] [Reference Citation Analysis]
382 Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci 2019;20:E952. [PMID: 30813239 DOI: 10.3390/ijms20040952] [Cited by in Crossref: 104] [Cited by in F6Publishing: 69] [Article Influence: 52.0] [Reference Citation Analysis]
383 Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers (Basel) 2018;10:E514. [PMID: 30558195 DOI: 10.3390/cancers10120514] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 16.3] [Reference Citation Analysis]
384 Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D. Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget 2018;9:36654-65. [PMID: 30613349 DOI: 10.18632/oncotarget.26336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
385 Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther 2013;12:1002-15. [PMID: 23729402 DOI: 10.1158/1535-7163.MCT-12-0813] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
386 Leamon CP, Lovejoy CD, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med 2013;6:113-25. [PMID: 24109193 DOI: 10.2147/PGPM.S24943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
387 Yi J, Liu C, Tao Z, Wang M, Jia Y, Sang X, Shen L, Xue Y, Jiang K, Luo F, Liu P, Cheng H. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine 2019;43:225-37. [PMID: 30898650 DOI: 10.1016/j.ebiom.2019.03.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
388 Senhaji Mouhri Z, Goodfellow E, Jean-Claude B. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. BMC Cancer 2017;17:540. [PMID: 28800752 DOI: 10.1186/s12885-017-3504-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
389 Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2013;31:213-29. [PMID: 22661305 DOI: 10.1007/s10637-012-9837-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
390 Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. JCI Insight 2021;6:138382. [PMID: 33470989 DOI: 10.1172/jci.insight.138382] [Reference Citation Analysis]
391 Baldock RA, Pressimone CA, Baird JM, Khodakov A, Luong TT, Grundy MK, Smith CM, Karpenshif Y, Bratton-Palmer DS, Prakash R, Jasin M, Garcin EB, Gon S, Modesti M, Bernstein KA. RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. DNA Repair (Amst) 2019;76:99-107. [PMID: 30836272 DOI: 10.1016/j.dnarep.2019.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
392 Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105:370-388. [PMID: 24484288 DOI: 10.1111/cas.12366] [Cited by in Crossref: 167] [Cited by in F6Publishing: 145] [Article Influence: 23.9] [Reference Citation Analysis]
393 Lung RW, Hau PM, Yu KH, Yip KY, Tong JH, Chak WP, Chan AW, Lam KH, Lo AK, Tin EK, Chau SL, Pang JC, Kwan JS, Busson P, Young LS, Yap LF, Tsao SW, To KF, Lo KW. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J Pathol 2018;244:394-407. [PMID: 29230817 DOI: 10.1002/path.5018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
394 Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget 2017;8:111026-40. [PMID: 29340034 DOI: 10.18632/oncotarget.22195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
395 Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes (Basel) 2020;11:E856. [PMID: 32726901 DOI: 10.3390/genes11080856] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
396 Mintz RL, Lao YH, Chi CW, He S, Li M, Quek CH, Shao D, Chen B, Han J, Wang S, Leong KW. CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells. Bioeng Transl Med 2020;5:e10152. [PMID: 31989039 DOI: 10.1002/btm2.10152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
397 Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A. GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. Future Sci OA 2019;5:FSO370. [PMID: 30820349 DOI: 10.4155/fsoa-2018-0107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
398 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 39] [Article Influence: 15.8] [Reference Citation Analysis]
399 Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol Oncol. 2019;153:127-134. [PMID: 30686551 DOI: 10.1016/j.ygyno.2019.01.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]